New hope for stomach cancer patients: triple-drug combo tested in clinical trial
NCT ID NCT07309185
First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 17 times
Summary
This study tests whether a combination of three drugs (adebrelimab, famitinib, and irinotecan) works better than irinotecan alone for people with advanced stomach cancer whose first treatment has stopped working. About 66 participants will be randomly assigned to one of the two groups. The goal is to see if the combo can delay cancer growth and improve survival, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong First Medical University Affiliated Cancer Hospital
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.